Browse existing research summaries on rapamycin and longevity science.
A meta-analysis of 911 effect sizes from 167 vertebrate studies reports that dietary restriction and rapamycin both extend lifespan, whereas metformin does not.
A review of mouse lifespan studies and human trials with rapamycin and rapalogs, arguing that the benefits of mTOR inhibition come from mTORC1 while most of the metabolic side effects come from mTORC2, so lower or intermittent dosing may widen the therapeutic window.
Reviews the mouse evidence that rapamycin extends lifespan and affects age-related conditions including cardiac function, the nervous system, immunity and cell senescence.
An editorial in Aging argues that longevity depends on communication between organelles and that the TOR pathway acts as the hub linking protein folding, metabolism and mitochondrial function.
A short research perspective arguing that dose, delivery route and treatment schedule must be studied to get rapamycin's benefits in mice with fewer side effects.
A review of mTOR biology and rapamycin as an anti-ageing compound argues that many of the drug's side effects are mediated by mTORC2 inhibition and may be separable from its lifespan-extending benefits.
